Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

ObjectiveBoth camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of local advanced or metastatic sqNSCLC. However, the co...

Description complète

Détails bibliographiques

Auteurs principaux:	Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, Chengwu Shen
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2024-07-01
Collection:	Frontiers in Pharmacology
Sujets:	cost-effectiveness squamous NSCLC first-line treatment camrelizumab sintilimab
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1356725/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!